National Osteoporosis Society Vitamin D Guideline Summary

Age and Ageing (Impact Factor: 3.64). 07/2014; 43(5). DOI: 10.1093/ageing/afu093
Source: PubMed


The National Osteoporosis Society (NOS) published its document, Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management, in 2013 as a practical clinical guideline on the management of vitamin D deficiency in adult patients with, or at risk of developing, bone disease. There has been no clear consensus in the UK on vitamin D deficiency its assessment and treatment, and clinical practice is inconsistent. This guideline is aimed at clinicians, including doctors, nurses and dieticians. It recommends the measurement of serum 25 (OH) vitamin D (25OHD) to estimate vitamin D status in the following clinical scenarios: bone diseases that may be improved with vitamin D treatment; bone diseases, prior to specific treatment where correcting vitamin D deficiency is appropriate; musculoskeletal symptoms that could be attributed to vitamin D deficiency. The guideline also states that routine vitamin D testing is unnecessary where vitamin D supplementation with an oral antiresorptive treatment is already planned and sets the following serum 25OHD thresholds: <30 nmol/l is deficient; 30-50 nmol/l may be inadequate in some people; >50 nmol/l is sufficient for almost the whole population. For treatment, oral vitamin D3 is recommended with fixed loading doses of oral vitamin D3 followed by regular maintenance therapy when rapid correction of vitamin D deficiency is required, although loading doses are not necessary where correction of deficiency is less urgent or when co-prescribing with an oral antiresorptive agent. For monitoring, serum calcium (adjusted for albumin) should be checked 1 month after completing a loading regimen, or after starting vitamin D supplementation, in case primary hyperparathyroidism has been unmasked. However, routine monitoring of serum 25OHD is generally unnecessary but may be appropriate in patients with symptomatic vitamin D deficiency or malabsorption and where poor compliance with medication is suspected. The guideline focuses on bone health as, although there are numerous putative effects of vitamin D on immunity modulation, cancer prevention and the risks of cardiovascular disease and multiple sclerosis, there remains considerable debate about the evaluation of extraskeletal factors and optimal vitamin D status in these circumstances.

Download full-text


Available from: William D Fraser, Aug 27, 2014
  • A Pines ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The easy access to measurement of serum 25-hydroxyvitamin D (vitD) levels created a surge in interest to learn more of its potential health benefits and its association with prevention of chronic diseases. VitD effects on bone and fracture risk were studied extensively, resulting in clinical guides that stress the need for adequate vitD supplementation. In addition, data are accumulating on its relevance to cardiovascular disease, cancer, cognition and other health domains. Recent studies and meta-analyses seem to lower this enthusiasm concerning the expected good outcomes of higher vitD levels in regard to reduction of risk for major chronic diseases in the general population. However, data are more supportive on various benefits in the case of vitamin D deficiency states, especially in older people. The following article is a short review of the latest developments in this regard.
    Climacteric 09/2014; 17(6):1-3. DOI:10.3109/13697137.2014.949232 · 2.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Children with epilepsy and intellectual disability have an increased risk of vitamin D deficiency. In this patient group, it is neither clear which factors are associated with the level of 25-hydroxyvitamin D nor what the therapeutic results are when Dutch guidelines are followed. This retrospective study included 30 patients who, in October 2012, were residents of the children's wards of a tertiary epilepsy center in The Netherlands (Kempenhaeghe). From November 2012 onward they received cholecalciferol supplementation in doses that met or exceeded Dutch guidelines. At baseline, after 6, and 15 months, serum 25-hydroxyvitamin D concentration was measured. At baseline, the vitamin D status in 11 (36.7%) residents was found to be deficient, in 10 (33.3%) to be insufficient and in 9 (30.0%) sufficient. Supplementation dose, diet, body mass index, intellectual disability, and mobility were significantly associated with baseline 25-hydroxyvitamin D concentrations. The mean 25-hydroxyvitamin D concentration increased significantly from 57.40 ± 22.00 nmol/L at baseline to 89.47 ± 26.77 nmol/L after 15 months (P < 0.001). In spite of supplementation ranging from 400 to 1200 IU/day, 64% of the residents in the deficient category and 30% of those with an insufficient level at baseline failed to attain a sufficient vitamin D status after 15 months. Not all residents reached a sufficient vitamin D status after supplementation at least equal to the amount recommended by the Dutch guidelines. In a high-risk population, such as our residents, we advise monitoring 25-hydroxyvitamin D concentrations, adjusting supplementation accordingly and following patients to ensure they reach sufficiency. Copyright © 2014 Elsevier Inc. All rights reserved.
    Pediatric Neurology 10/2014; 52(2). DOI:10.1016/j.pediatrneurol.2014.10.001 · 1.70 Impact Factor
  • Source

    Maturitas 11/2014; 80(2). DOI:10.1016/j.maturitas.2014.11.018 · 2.94 Impact Factor
Show more